Empo Health Achieves Major Milestones in Foot Health Technology and Safety Standards

Empo Health's Groundbreaking Achievements

Empo Health, Inc. has marked three major advancements that signal its commitment to transforming foot care through technology. On July 30, 2026, the company announced the publication of a peer-reviewed study, the receipt of the APMA Seal of Approval, and successful SOC 2 Type 2 compliance, showcasing its dedication to both clinical effectiveness and data security.

Peer-Reviewed Publication

In an important step for its credibility, Empo Health’s trial results have been published in JMIR Formative Research, a renowned peer-reviewed journal. This study evaluated the usability of the Empo Footprint system in the homes of 21 adult patients with a history of diabetic foot ulcers. Conducted over seven months, the findings revealed astonishing adherence rates: patients utilized the device a median of 27 times out of 30 days, providing an impressive level of engagement. Among the 3,295 scans reviewed, podiatrists rated a remarkable 97.7% as clinically acceptable for remote assessments.

Noteworthy outcomes included the identification of urgent medical concerns such as emergent wounds and foreign bodies—critical findings that affirm the durability and real-world applicability of the Empo Footprint in preventive foot health.

Anuj Khandelwal, co-founder and CEO, emphasized the significance of this research: "Publishing real-world experiences reinforces the clinical evidence required by healthcare systems and payor partners. We are demonstrating that high-risk patients can effectively use our technology at home, which is vital for the success of value-based care models."

APMA Seal of Approval

Additionally, both the Empo Footprint and the Empo Remote Health Link have been granted the esteemed APMA Seal of Approval. This accolade, awarded by the American Podiatric Medical Association—an organization representing over 15,000 podiatrists—reflects Empo’s adherence to the highest standards of foot health promotion.

"Receiving the APMA Seal is a significant validation from leading professionals in podiatry," Khandelwal remarked. He highlighted the importance of this recognition for health systems, as it assures that the technology meets the rigorous standards set by the nation's podiatric leaders.

SOC 2 Type 2 Compliance

Complementing these achievements, Empo Health successfully completed a SOC 2 Type 2 audit, confirming that its patient data protection measures meet the stringent security trust services criteria. This independent validation enhances trust among healthcare organizations that engage with Empo's systems.

As Eric Dahlseng, co-founder and Chief Product Officer, stated, "Having independent confirmation of our data handling assurance is essential for collaboration with payors and health systems. Achieving SOC 2 compliance lifts a significant barrier for enterprise adoption by ensuring our controls function as intended consistently."

About Empo Health

Empo Health is a healthcare technology firm that specializes in improving health outcomes through innovative in-home monitoring devices. Founded in 2020 by a team with backgrounds from MIT and Stanford, the company is based in Silicon Valley and is bolstered by venture capital and government grants. Empo’s flagship products, the FDA-listed Empo Footprint and HIPAA-compliant Empo Remote Health Link, are designed to help in monitoring diabetic foot conditions by facilitating regular assessments of foot skin conditions and weight management. It is important to note that these devices act as monitoring tools rather than standalone diagnostic instruments. Empo Health continues to lead the charge in enhancing patient care in the realms of diabetes and preventive foot health management.